Boehringer and Lilly to assess empagliflozin for chronic kidney disease

Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news